Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (recombinant), quadrivalent
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Quadrivalent RIV (Recombinant Influenza Vaccine) is a vaccine formulation containing four recombinant hemagglutinin (HA) proteins, typically representing two Influenza A strains (H1N1 and H3N2) and two Influenza B lineages (Victoria and Yamagata). Developed by Sanofi (following the acquisition of Protein Sciences), the most prominent version is marketed as Flublok Quadrivalent. Unlike traditional egg-based vaccines, RIV is produced using a baculovirus expression system in insect cells (Sf9 cells), which eliminates the risk of egg-adaptive mutations and allows for a higher antigen concentration (45 mcg per strain compared to 15 mcg in standard vaccines). Clinical development continues for optimized formulations, including those with different H3 antigens or the addition of adjuvants to enhance immunogenicity, particularly in older adults.
- Brand names
- Flublok Quadrivalent
- Other names
- quadrivalent recombinant influenza vaccinerecombinant influenza vaccine, quadrivalent
02
Targets
Influenza hemagglutinin-specific B-cell receptorT-cell receptor specific for influenza hemagglutinin peptide-MHC class II complexHA0 (Influenza B virus hemagglutinin)HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza vaccine (recombinant), quadrivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (recombinant), quadrivalent.